ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

resiquimod

Also written as “BDB-001 injection”, “EIK1001” and “BDB-001 Injection”.

Its studies are mostly in Neoplasms · Neoplasm Metastasis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · COVID-19 · Hidradenitis Suppurativa, led by 2 companies.

Drug pageBDB001: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 26, 202014 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Staidson (Beijing) Biopharmaceuticals81 open or runningphase 3since Jun 26, 2020Jun 26, 2020Apr 16, 2027phase 3 · NCT07168161
Eikon Therapeuticsits history only63 open or runningphase 3since Nov 18, 2024Feb 28, 2018Dec 2026phase 2 · NCT06246110

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Staidson (Beijing) Biopharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2019Named resiquimodINNProposed as its International Nonproprietary Name in WHO's List 122 · before, EIK1001, BDB001
  2. Jun 26, 2020First study: phase 3 study in COVID-19First studyNCT04449588 · 369 enrolled · Bangladesh, China, India and more
  3. Jun 23, 20212 phase 2 studies in Hidradenitis SuppurativaNCT05103423, NCT05093855
  4. Aug 22, 2021Phase 1 study in COVID-19NCT05075304 · 18 enrolled · China
  5. Dec 2, 2021Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT05197842 · 93 enrolled · China
  6. Apr 29, 20222 phase 1 studies in HealthyNCT05361005, NCT05360927
  7. Sep 4, 2025Phase 3 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07168161 · 300 planned · China

Ahead

  1. Apr 16, 2027Primary completion: phase 3 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07168161

TargetBeta

TLR7 →TLR8 →read by rule
“The sulfate salt form of resiquimod, a toll-like receptor type 7 and 8 (TLR7/8) agonist, ”NCIt, by rule
“Toll-like receptor 8 agonist; Toll-like receptor 7 agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
enpatoranruleMerck KGaA, Darmstadt, Germanyphase 312
afimetoranruleBristol-Myers Squibbphase 312

Studies

All 8 Staidson (Beijing) Biopharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07168161Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China3RecruitingApr 16, 2027300
NCT05361005Healthy · China1CompletedMay 8, 202033
NCT05360927Healthy · China1CompletedDec 25, 202028
NCT05197842Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China2CompletedMar 19, 202593
NCT05075304COVID-19 · China1TerminatedApr 14, 202018
NCT05103423Hidradenitis Suppurativa · China2CompletedJul 7, 202350
NCT05093855Hidradenitis Suppurativa · China2CompletedAug 22, 202341
NCT04449588COVID-19 · Bangladesh, China, India and more3TerminatedMar 26, 2024369

How it is read

Names in the registry

  • “BDB-001 injection”, 7 entries
  • “EIK1001”, 3 entries
  • “BDB-001 Injection”, 3 entries
  • “BDB001 (EIK1001)”, 2 entries
  • “BDB001”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.